SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-064785
Filing Date
2024-03-11
Accepted
2024-03-11 16:03:03
Documents
14
Period of Report
2024-03-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d640442d8k.htm   iXBRL 8-K 22796
  Complete submission text file 0001193125-24-064785.txt   140329

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eigr-20240308.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20240308_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20240308_pre.xml EX-101.PRE 10815
15 EXTRACTED XBRL INSTANCE DOCUMENT d640442d8k_htm.xml XML 3495
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 24737934
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)